和誉(02256)午后涨近12% 将在美国血液学会年会发布CSF-1R抑制剂匹米替尼II期研究数据

金吾财讯2024-11-08

金吾财讯 | 和誉(02256)股价午后拉升，截至发稿，涨11.79%，报4.93港元，成交额3875.36万港元。

公司公布，附属和誉医药将在第66届美国血液学会(“ASH”)年会(将于2024年12月7日至10日在美国加利福尼亚州的圣地亚哥举行)上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼(ABSK021)的一项II期研究数据。

此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性移植物抗宿主病 (cGvHD)患者的应用情况。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481611200?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg","is_english":false,"pubTime":"2024-11-08 14:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481611200","market":"sh","top_or_hot":-1,"title":"和誉(02256)午后涨近12% 将在美国血液学会年会发布CSF-1R抑制剂匹米替尼II期研究数据","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 和誉(02256)股价午后拉升，截至发稿，涨11.79%，报4.93港元，成交额3875.36万港元。</p><p>公司公布，附属和誉医药将在第66届美国血液学会(“ASH”)年会(将于2024年12月7日至10日在美国加利福尼亚州的圣地亚哥举行)上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼(ABSK021)的一项II期研究数据。</p><p>此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性移植物抗宿主病 (cGvHD)患者的应用情况。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和誉(02256)午后涨近12% 将在美国血液学会年会发布CSF-1R抑制剂匹米替尼II期研究数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和誉(02256)午后涨近12% 将在美国血液学会年会发布CSF-1R抑制剂匹米替尼II期研究数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 14:48 北京时间&nbsp;&nbsp;&nbsp;<a href=1947379><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 和誉(02256)股价午后拉升，截至发稿，涨11.79%，报4.93港元，成交额3875.36万港元。公司公布，附属和誉医药将在第66届美国血液学会(“ASH”)年会(将于2024年12月7日至10日在美国加利福尼亚州的圣地亚哥举行)上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼(ABSK021)的一项II期研究数据。此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性...</p>\n\n<a href=\"1947379\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSF","symbol_name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","start_time":0,"source_url":"1947379","article_id":"2481611200","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481611200","pubTimestamp":1731048493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 和誉(02256)股价午后拉升，截至发稿，涨11.79%，报4.93港元，成交额3875.36万港元。公司公布，附属和誉医药将在第66届美国血液学会(“ASH”)年会(将于2024年12月7日至10日在美国加利福尼亚州的圣地亚哥举行)上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼(ABSK021)的一项II期研究数据。此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性移植物抗宿主病 (cGvHD)患者的应用情况。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CSF":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","02256":"和誉-B"},"translate_title":"Heyu (02256) rose nearly 12% in the afternoon and will release data from the phase II study of CSF-1R inhibitor pimetinib at the annual meeting of the American Society of Hematology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSF":1,"02256":1},"content_text":"金吾财讯 | 和誉(02256)股价午后拉升，截至发稿，涨11.79%，报4.93港元，成交额3875.36万港元。公司公布，附属和誉医药将在第66届美国血液学会(“ASH”)年会(将于2024年12月7日至10日在美国加利福尼亚州的圣地亚哥举行)上以口头报告形式发布其自主研发的CSF-1R抑制剂匹米替尼(ABSK021)的一项II期研究数据。此研究调查匹米替尼于治疗既往一线或多线治疗失败的慢性移植物抗宿主病 (cGvHD)患者的应用情况。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481611200","isCrawlerRequest":true}